Voretigene neparvovec (LUXTURNA) is a gene therapy proposed for the treatment of patients with vision loss due to confirmed biallelic RPE65 mutation-associated retinal dystrophy. This condition leads to progressive, severe vision loss and often results in total blindness in early adulthood. There are currently no approved pharmacological treatments, representing a significant unmet medical need.

This BLA is supported by a clinical program that includes a Phase 1 dose-escalation study (Studies 101/102, n=12) and a pivotal, open-label, randomized, controlled Phase 3 study (Study 301, n=31). LUXTURNA has received Orphan Drug, Breakthrough Therapy, and Rare Pediatric Disease designations from the FDA.

The Phase 3 study provides the primary evidence of efficacy. Subjects were randomized 2:1 to receive sequential subretinal injections of LUXTURNA (n=21) or serve as controls (n=10) for one year, after which the control group could cross over to receive treatment. The primary endpoint was the mean change from baseline to Year 1 in the multi-luminance mobility test (MLMT) score. The MLMT is a novel, validated endpoint designed to measure changes in functional vision by assessing a subject's ability to navigate a standardized course at seven different levels of illumination.

The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in functional vision for the treatment group compared to controls. The mean MLMT score change was 1.8 in the treatment group versus 0.2 in the control group (p=0.001). This improvement was observed by Day 30 and was sustained through the two-year follow-up period.

The safety population includes 41 subjects from the Phase 1 and 3 studies. The majority of adverse events were ocular and related to the subretinal injection procedure. The most common adverse reactions were conjunctival hyperemia, cataract, and increased intraocular pressure. These events were generally transient and manageable. Two serious adverse events, endophthalmitis and permanent vision loss (related to retinal thinning at the injection site in an atrophic retina), were reported and are considered risks of the procedure. Immunogenicity was limited and had no clinical sequelae.

In conclusion, the data demonstrate that LUXTURNA provides a durable and clinically meaningful improvement in functional vision. The risks, primarily associated with the administration procedure, are well-characterized and can be managed with proper surgical technique and monitoring. The benefit-risk assessment is strongly positive, supporting the approval of LUXTURNA for this patient population with a profound unmet medical need.